经导管动脉内化疗栓塞术联合载多柔比星微球治疗不可切除或复发性结直肠癌。
Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer.
机构信息
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, 450052, China.
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, 450052, China.
出版信息
Abdom Radiol (NY). 2021 Jun;46(6):2833-2838. doi: 10.1007/s00261-020-02877-w. Epub 2021 Jan 2.
PURPOSE
We aimed to assess the safety and efficacy of transarterial chemoembolization (TACE) with doxorubicin-loaded CalliSpheres beads (DEB-TACE) for the treatment of patients with inoperable or recurrent colorectal cancer (CRC).
METHODS
This retrospective study recruited 12 consecutive patients with histology confirmation of CRC who received DEB-TACE between August 2017 and April 2020. There were 9 male and 3 female, with a mean age 62.5 ± 14.9 (range 29-84). Patients' characteristics, medical imaging data, complications and DEB-TACE procedure were retrospectively reviewed. The disease control rate was defined as the sum of complete response, partial response and stable disease.
RESULTS
DEB-TACE was successfully performed in all patients. All patients showed local disease control 1 month after DEB-TACE. Disease control rates were 90.9% and 70.0% at 3 and 6 months after DEB-TACE procedure, respectively. Disease-free interval was 11.0 to 81.8 months. Five patients (41.7%) received prior chemotherapy treatments. No severe complications or procedure-related deaths were observed. The median overall survival was 15.9 months, and median progression-free survival was 13.4 months.
CONCLUSION
DEB-TACE is a safe and effective treatment and could be a option for patients with inoperable or recurred CRC.
目的
我们旨在评估载多柔比星 CalliSpheres 微球（DEB-TACE）的经动脉化疗栓塞（TACE）治疗不可切除或复发性结直肠癌（CRC）患者的安全性和疗效。
方法
本回顾性研究招募了 2017 年 8 月至 2020 年 4 月期间接受 DEB-TACE 治疗的 12 例经组织学证实为 CRC 的连续患者。其中男性 9 例，女性 3 例，平均年龄 62.5±14.9（范围 29-84）。回顾性分析了患者的特征、医学影像学数据、并发症和 DEB-TACE 程序。疾病控制率定义为完全缓解、部分缓解和稳定疾病的总和。
结果
所有患者均成功完成了 DEB-TACE。所有患者在 DEB-TACE 后 1 个月均显示局部疾病控制。DEB-TACE 后 3 个月和 6 个月的疾病控制率分别为 90.9%和 70.0%。无疾病间隔为 11.0 至 81.8 个月。5 例（41.7%）患者接受了先前的化疗治疗。未观察到严重并发症或与程序相关的死亡。中位总生存期为 15.9 个月，中位无进展生存期为 13.4 个月。
结论
DEB-TACE 是一种安全有效的治疗方法，可为不可切除或复发性 CRC 患者提供一种选择。
Zotero 插件